Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr 29:17:79-83.
doi: 10.2147/CPAA.S515122. eCollection 2025.

A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review

Jingyi Yang #  1   2   3 , Qian Shen #  1   4 , Xiaoyan Ke  5 , Wei Liu  1   3 , Ping Yang  5
Affiliations
Case Reports

A Case Report of Sustained Cytokine Release Syndrome Due to Glofitamab and Literature Review

Jingyi Yang et al. Clin Pharmacol. .

Abstract

Glofitamab is a novel bispecific antibody targeting CD20×CD3, capable of simultaneously targeting CD20 and CD3 to activate T cells and release cytotoxic proteins that kill cancer cells. Cytokine release syndrome (CRS) is one of the most common adverse events observed in clinical trials of glofitamab. In most cases, CRS is mild, transient, and manageable with appropriate treatment. This paper reports a case of persistent CRS in a patient with mantle cell lymphoma following glofitamab treatment and reviews the relevant literature for reference.

Keywords: cytokine release syndrome; cytokines; glofitamab; interleukin-6.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests in this work.

Figures

Figure 1
Figure 1
Cytokine changes in patients during glofitamab treatment (pg/mL).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Clinical guidelines for the treatment of diffuse large B-cell lymphoma with gefituzumab (2024 edition). Leukemia Lymphoma. 2018;05(33):257–264.
    1. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment. Available from: http://who-umc.org/Graphics/24734.pdf. Accessed April 24, 2025.
    1. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978–3992. doi:10.1200/JCO.21.01992 - DOI - PubMed
    1. Hsu YT, J WS, Kao HW, et al. Glofitamab as a salvage treatment for B-cell lymphomas in the real world: a multicenter study in Taiwan. Cancer. 2024;130(11):1972–1981. doi:10.1002/cncr.35217 - DOI - PubMed
    1. Moore DC, Digiantonio N, Oxencis CJ, Taucher KD. Pharmacist perspectives on emerging T cell-engaging bispecific therapies in cancer therapeutics. Am J Health Syst Pharm. 2024;81(14):574–582. doi:10.1093/ajhp/zxae050 - DOI - PubMed

Publication types

LinkOut - more resources